提供学术论文选刊润色服务
医学
医学
Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
70
天
Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21
作者Muloongo Simuzingili; Zinan Yi; Andrea Favre-Bulle; Thomas Mutschler; Eleana Tsoumani; Kwame Owusu-Edusei
作者单位1. Merck & Co., Inc; 2. MSD Switzerland; 3. MSD Greece
114
天
Projected burden of bloodstream infections and the impact of molecular rapid diagnostic testing on costs and mortality in England and the United States (2025–2029): a population-level budget impact analysis
作者James K. Karichu; Mark Pennington; Kiera Lander; Tiffeny T. Smith; Adam Thornberg
作者单位1. Roche Molecular Systems; 2. Source Health Economics; 3. Roche Diagnostics Corporation
62
天
Societal and fiscal gains from HPV vaccination in Poland – return on investment from extending access to HPV vaccination
作者Rafal Jaworski; Nikolaos Kotsopoulos; Marcin Czech; Mark P. Connolly; Andrew Pavelyev; Alicja Wojcik; Ugne Sabale
作者单位1. Market Access Department, MSD; 2. Global Market Access Solutions Sàrl; 3. University of Athens; 4. Pharmacoeconomic Department, Institute of Mother and Child; 5. University Groningen; 6. Health Economic and Decision Sciences, Merck & Co., Inc; 7. Value & Implementation Outcomes Research, MSD Vilnius
41
天
Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non–BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan
作者Akira Yuasa; Mitsuhiro Nagano; Yoichi Kamei; Kengo Hatsuyama; Hiroyuki Matsuda; Patrick Hlavacek; Marco DiBonaventura; Kenshi Suzuki
作者单位1. Japan Access & Value, Pfizer Japan Inc; 2. Pfizer R&D Japan G.K; 3. Real World Evidence Solutions & HEOR, IQVIA Solutions Japan G.K; 4. HTA, Value & Evidence, Pfizer Inc; 5. Myeloma/AL Amyloid Unit, Japanese Red Cross Medical Center
42
天
Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis
作者Tendai Mugwagwa; Benjamin A. Abramoff; Siddharth Karanth; Tram Nham; Ravi K. Goyal; Elizabeth Esterberg; Gurinder S. Sidhu; Alon Yehoshua; Ruth Mokgokong
作者单位1. Pfizer Ltd; 2. University of Pennsylvania; 3. RTI Health Solutions; 4. Pfizer Inc
53
天
Cost-effectiveness analysis of Cardioform vs. Amplatzer: concerns regarding methodological transparency and interpretation of clinical results
作者David W. Hutton; Anne M. Ryschon; Scott Goates; Jan B. Pietzsch; Lars Søndergaard
作者单位1. Department of Health Management and Policy, University of Michigan; 2. Wing Tech Inc; 3. Global Data Science and Analysis; 4. Abbott, CA, USA
54
天
Budget impact analysis for albuterol–budesonide fixed-dose combination in the as needed treatment of adult patients with asthma in Kuwait
作者Gihan Hamdy Elsisi; Mohamed Al-Bader; Hanan Al-Razzuqi; Muneera Al-Asfoor; Nawaf Dehrab; Mohamed M. Ibrahim; Mona Al-Ahmad
作者单位1. HTA Office, LLC; 2. Economics Department, American University; 3. Pulmonology Department, Seef Hospital; 4. Emergency Department, Farwaniya Hospital; 5. Emergency Department, Amiri Hospital; 6. Emergency Department, Adan Hospital; 7. Department of Medicine, Jaber Al-Ahmed Armed Forces Hospital, Ministry of Defense; 8. Pulmonology Department, Allergy Center
64
天
Cost-effectiveness of nicotine metabolite ratio-guided smoking cessation therapy in China: a hybrid decision-analytic modeling study based on real-world data
作者Anqi Cheng; Min Wang; Yingman Gao; Tingfen Ji; Xuejun Hu; Xue Yu; Yong Qi; Wenli Chen; Suqin Xu; Zhao Liu; Xinmei Zhou; Dan Xiao; Chen Wang
作者单位1. Department of Tobacco Control and Prevention of Respiratory Diseases, Center of Respiratory Medicine, China-Japan Friendship Hospital; 2. WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention; 3. National Center for Respiratory Medicine; 4. State Key Laboratory of Respiratory Health and Multimorbidity; 5. National Clinical Research Center for Respiratory Diseases; 6. China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College; 7. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College; 8. Capital Medical University China-Japan Friendship School of Clinical Medicine; 9. Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University; 10. Department of Respiratory and Critical Care, Tengzhou Central People’s Hospital; 11. Department of Pulmonary and Critical Care Medicine, Henan Provincial People’s Hospital; 12. Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Chengde Medical College; 13. Department of Pulmonary and Critical Care Medicine, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology; 14. Peking Union Medical College, Chinese Academy of Medical Sciences
69
天
Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis
作者Alon Yehoshua; Rachel M. Black; Anan Zhou; Michelle A. Silver; Yu Han; Santiago M. C. Lopez; Benjamin Yarnoff; Rajeev M. Nepal; Maria M. Fernandez; Mohammad Ashraf Chaudhary; Tara Ahi
作者单位1. Pfizer Inc; 2. AESARA Inc; 3. Genesis Research Group; 4. Thermo Fisher Scientific
105
天
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿96.4 天
中位数77 天